Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Viatris Inc — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2.7× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Viatris Inc pays a 2.75% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 32 Days and Viatris Inc for 57 Days on average.
| SPXL | VTRS | |
|---|---|---|
Market Cap | $7.36B | $20.03B |
Volume | 1,835,467 | 14,109,977 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $18.27 |
52-Week Low | $170.20 | $9.74 |
Typical Hold Time | 32 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL, a leveraged ETF tracking the S&P 500, trades at $293.05, down 1.28% on the day. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETF reflects broader market sentiment where S&P 500 earnings are expected to grow 35% in 2026 (24/7 Wall Street, 2026-10-03), yet concerns about profit growth slowing to 15% in 2027 and high concentration in top holdings create uncertainty.
The outlook for SPXL is tied to S&P 500 performance, with Wall Street projecting a 21% rise to 9,275 by September 2027 (The Motley Fool, 2026-09-30). Key risks include market volatility, geopolitical tensions, and slowing earnings growth. Opportunities lie in seasonal bullish trends and AI-driven corporate spending, but leveraged exposure amplifies both gains and losses.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
